Acurx Pharmaceuticals Inc 2025年季度报告

FORM10-Q (Mark one) For the Quarterly Period EndedSeptember 30, 2025 Or (Exact name of registrant as specified in its charter) 10305(Zip Code) Securities registered pursuant to Section12(b)of the Act: Name of each exchange on whichregisteredTheNasdaqCapital Market Indicate by check mark whether the registrant (1)has filed all reports required to be filed by Section13 or 15(d)of theSecurities Exchange Act of 1934 during the preceding 12months (or for such shorter period that the registrant wasrequired to file such reports), and (2)has been subject to such filing requirements for the past 90days.☒Yes☐No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to besubmitted pursuant to Rule405 of Regulation S-T (§232.405 of this chapter) during the preceding 12months (or for suchshorter period that the registrant was required to submit such files).☒Yes☐No Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, asmaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “acceleratedfiler,” “smaller reporting company,” and “emerging growth company” in Rule12b-2 of the Exchange Act. Accelerated filer☐ Large accelerated filer☐ Non-accelerated filer☒ Smaller reporting company☒ Emerging growth company☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transitionperiod for complying with any new or revised financial accounting standards provided pursuant to Section13(a)of theExchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Exchange Act).☐Yes☒No As of November 11, 2025, there were2,085,363shares of common stock, $0.001 par value, issued and outstanding. Acurx Pharmaceuticals,Inc. Table ofContents PARTI-FINANCIAL INFORMATION5Item1.Condensed Interim Financial Statements5Condensed Interim Balance Sheets as of September 30, 2025 (unaudited) and December31, 20245Condensed Interim Statements of Operations for the Three and Nine Months Ended September 30,2025 and 2024 (unaudited)6Condensed Interim Statements of Changes in Shareholders’ Equity for the Three and Nine MonthsEnded September 30, 2025 and 2024 (unaudited)7Condensed Interim Statements of Cash Flows for the Nine Months Ended September 30, 2025 and2024 (unaudited)9Notesto the Condensed Interim Financial Statements (unaudited)10Item2.Management’s Discussion and Analysis of Financial Condition and Results of Operations20Item3.Quantitative and Qualitative Disclosures about Market Risk29Item4.Controls and Procedures29PARTII-OTHER INFORMATION30Item1.Legal Proceedings30Item1A.Risk Factors30Item2.Unregistered Sales of Equity Securities and Use of Proceeds65Item3.Defaults Upon Senior Securities65Item4.Mine Safety Disclosure65Item5.Other Information65Item6.Exhibits66Signatures67Certificates SPECIAL NOTEREGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form10-Q (“Quarterly Report”) and certain information incorporated herein byreference contain forward-looking statements within the meaning of Section27A of the Securities Act of 1933, asamended (the “Securities Act”), and Section21E of the Securities Exchange Act of 1934, as amended (the “ExchangeAct”). In this Quarterly Report, we refer to Acurx Pharmaceuticals,Inc., together with its subsidiary, as the“Company,” “we,” “our” or “us.” All statements other than statements of historical facts contained herein, includingstatements regarding our future results of operations and financial position, strategy and plans, and our expectationsfor future operations, are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “continue,”“anticipate,” “design,” “intend,” “expect” or the negative version of these words and similar expressions are intendedto identify forward-looking statements. We have based these forward-looking statements on our current expectations and projections about futureevents and trends that we believe may affect our financial condition, results of operations, strategy, short- and long-term business operations and objectives, and financial needs. These forward-looking statements are subject to anumber of risks, uncertainties and assumptions, including those described in PartII, Item1A “Risk Factors.” In lightof these risks, uncertainties and assumptions, the forward-looking events and circumstances included herein may notoccur, and actual results could differ materially and adversely from those anticipated or implied in the forward-lookingstatements. Given these uncertainties, you should not place undue reliance on these forward-looking statements.Forward-looking statements include, but are not limited to, statements about: ●our ability to obtain and maintain regulatory approval of ibezapolstat and/or our other productcandidates;●our ability to successfully commercialize a